Correlation Between Europlasma and Acticor Biotech

Can any of the company-specific risk be diversified away by investing in both Europlasma and Acticor Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Europlasma and Acticor Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Europlasma SA and Acticor Biotech SAS, you can compare the effects of market volatilities on Europlasma and Acticor Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Europlasma with a short position of Acticor Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Europlasma and Acticor Biotech.

Diversification Opportunities for Europlasma and Acticor Biotech

0.56

Correlation Coefficient

Europlasma  Acticor Biotech

Very weak diversification

The 3 months correlation between Europlasma and Acticor is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Europlasma SA and Acticor Biotech SAS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acticor Biotech SAS and Europlasma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Europlasma SA are associated (or correlated) with Acticor Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acticor Biotech SAS has no effect on the direction of Europlasma i.e., Europlasma and Acticor Biotech go up and down completely randomly.

Pair Corralation between Europlasma and Acticor Biotech

Assuming the 90 days trading horizon Europlasma SA is expected to under-perform the Acticor Biotech. In addition to that, Europlasma is 2.54 times more volatile than Acticor Biotech SAS. It trades about -0.02 of its total potential returns per unit of risk. Acticor Biotech SAS is currently generating about 0.0 per unit of volatility. If you would invest  740.00  in Acticor Biotech SAS on October 10, 2024 and sell it today you would lose (715.00) from holding Acticor Biotech SAS or give up 96.62% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Europlasma SA  vs.  Acticor Biotech SAS

Europlasma SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Europlasma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Acticor Biotech SAS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acticor Biotech SAS has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Europlasma and Acticor Biotech

The main advantage of trading using opposite Europlasma and Acticor Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Europlasma position performs unexpectedly, Acticor Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acticor Biotech will offset losses from the drop in Acticor Biotech's long position.

The idea behind Europlasma SA and Acticor Biotech SAS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.